VivoSim Labs, INC.

VivoSim Labs, INC. (ticker: VIVS) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of VIVS's SEC filings surfaces 5 active risk signals, including 3 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. VIVS reported $91K in revenue and -$8.08M for the period ending 2025-12-31, with operating cash flow of -$8.59M. Cash and equivalents stood at $4.29M (up 269.3% year-over-year). Total assets of $6.96M exceed total liabilities of $2.52M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

VIVS Cash Runway

Months-of-runway analysis for VIVS, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on VIVS

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.